IMCR241220C30000
- 6.00
- 0.000.00%
Immunocore Newsroom
Corcept Shares Rise More Than 60% in Three Months: Here's Why
Goldman Sachs Maintains Immunocore(IMCR.US) With Buy Rating, Announces Target Price $74
BioPharma Credit Receives Full Prepayment of Term Loan to Immunocore
Immunocore Hldgs Analyst Ratings
Mizuho Securities Downgrades Immunocore(IMCR.US) to Hold Rating, Cuts Target Price to $38
Express News | Immunocore : Mizuho Cuts to Neutral From Outperform
Immunocore Holdings Prepares Early Loan Agreement Termination
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know
Immunocore to Present at Upcoming Investor Conferences
Morgan Stanley Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $74
Oppenheimer Trims Immunocore Price Target to $88 From $89, Maintains Outperform Rating
Barclays Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $66
Barclays Keeps Their Buy Rating on Immunocore Holdings (IMCR)
Immunocore Holdings Plc Reports Strong Q3 Revenue Growth
Needham Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $71
TD Cowen Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $60
Express News | Immunocore : TD Cowen Cuts Target Price to $60 From $90
Immunocore Holdings: Strong Market Performance and Promising Pipeline Drive Buy Rating
Immunocore | 8-K: Immunocore reports third quarter financial results and provides a business update
Immunocore Hldgs Q3 2024 GAAP EPS $0.17 May Not Be Comparable To $(0.35) Estimate, Sales $80.25M Miss $80.60M Estimate